AbbVie Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de AbbVie de 23.4% y 5.3% por año respectivamente. Se prevé que el BPA crezca en un 23.3% al año. Se espera que la rentabilidad financiera sea de 184% en 3 años.

Información clave

23.3%

Tasa de crecimiento de los beneficios

22.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.0%
Tasa de crecimiento de los ingresos	5.6%
Rentabilidad financiera futura	184.3%
Cobertura de analistas	Good
Última actualización	03 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade)

Jan 30

AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.55

Jan 05

AbbVie: Time To Lock In Gains (Rating Downgrade)

Jan 03

AbbVie Vs. GSK: Dual Dominance In Pharma

Dec 23

AbbVie's (NYSE:ABBV) Upcoming Dividend Will Be Larger Than Last Year's

Dec 12

4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024

Nov 29

AbbVie (NYSE:ABBV) Has Announced That It Will Be Increasing Its Dividend To $1.55

Nov 28

AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks

Nov 21

AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.55

Oct 30

AbbVie Stock Still A Hold Despite Positive Third Quarter 2023 Results

Oct 30

AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldn't Derail Growth Plans

Oct 23

AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014

Oct 16

Previsiones de crecimiento de beneficios e ingresos

NYSE:ABBV - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	62,133	13,290	25,612	N/A	21
12/31/2025	57,951	10,975	23,737	N/A	25
12/31/2024	54,913	8,217	19,094	N/A	25
3/31/2024	54,403	5,950	N/A	N/A	N/A
12/31/2023	54,318	4,820	22,062	22,839	N/A
9/30/2023	55,138	6,471	24,729	25,514	N/A
6/30/2023	56,023	8,635	24,799	25,542	N/A
3/31/2023	56,741	7,542	23,520	24,228	N/A
12/31/2022	58,054	11,782	24,248	24,943	N/A
9/30/2022	57,819	13,343	21,921	22,590	N/A
6/30/2022	57,349	12,569	22,214	22,923	N/A
3/31/2022	56,725	12,407	22,047	22,808	N/A
12/31/2021	56,197	11,468	21,990	22,777	N/A
9/30/2021	55,169	7,465	21,677	22,556	N/A
6/30/2021	53,729	6,599	19,572	20,451	N/A
3/31/2021	50,195	5,092	17,789	18,650	N/A
12/31/2020	45,804	4,556	16,790	17,588	N/A
9/30/2020	40,650	7,324	15,327	16,009	N/A
6/30/2020	36,227	6,906	14,115	14,734	N/A
3/31/2020	34,057	8,395	13,552	14,122	N/A
12/31/2019	33,266	7,842	12,772	13,324	N/A
9/30/2019	32,867	3,232	12,929	13,441	N/A
6/30/2019	32,624	4,093	12,770	13,410	N/A
3/31/2019	32,647	5,333	13,173	13,799	N/A
12/31/2018	32,753	5,657	12,789	13,427	N/A
9/30/2018	32,187	7,531	11,922	12,619	N/A
6/30/2018	30,946	6,419	10,825	11,366	N/A
3/31/2018	29,612	6,352	9,950	10,503	N/A
12/31/2017	28,216	5,283	N/A	9,960	N/A
9/30/2017	27,273	6,615	N/A	8,917	N/A
6/30/2017	26,710	6,582	N/A	7,100	N/A
3/31/2017	26,218	6,278	N/A	7,015	N/A
12/31/2016	25,638	5,923	N/A	7,041	N/A
9/30/2016	25,242	6,048	N/A	7,463	N/A
6/30/2016	24,754	5,690	N/A	8,164	N/A
3/31/2016	23,777	5,448	N/A	8,078	N/A
12/31/2015	22,859	5,118	N/A	7,535	N/A
9/30/2015	21,911	2,790	N/A	4,994	N/A
6/30/2015	20,986	2,064	N/A	4,625	N/A
3/31/2015	20,437	1,802	N/A	4,510	N/A
12/31/2014	19,960	1,765	N/A	3,549	N/A
9/30/2014	19,619	3,686	N/A	5,372	N/A
6/30/2014	19,258	4,144	N/A	5,384	N/A
3/31/2014	19,024	4,114	N/A	5,704	N/A
12/31/2013	18,790	4,102	N/A	6,267	N/A
9/30/2013	18,885	4,540	N/A	5,963	N/A
6/30/2013	18,735	5,161	N/A	6,414	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (23.4% al año) de ABBV es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (23.4% al año) de ABBV crezcan más rápidamente que el mercado US (14.7% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de ABBV crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (5.3% al año) de ABBV crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 5.3% al año) de ABBV crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de ABBV sea muy elevada dentro de 3 años (184%).

AbbVie Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 13%

Recent updates

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

AbbVie's Q1: Positive Surprise

AbbVie Inc. Announces Positive Topline Results from Level Up

AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients with Giant Cell Arteritis

AbbVie: Great To Be Proven Wrong - Still Not A Buy

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

Upcoming dividend of US$1.55 per share

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

AbbVie Announces U.S. Food and Drug Administration Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

Executive VP & Chief Commercial Officer recently sold US$5.9m worth of stock

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie: Strong Cash Flow Growth Fuels Dividend Growth

AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios

New minor risk - Insider selling

Chairman & CEO recently sold US$25m worth of stock

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Executive VP & COO notifies of intention to sell stock

Full year 2023 earnings: EPS misses analyst expectations

AbbVie Inc. Announces Chief Executive Officer Changes

Abbvie, Inc. Appoints Robert A. Michael as Member of the Board of Directors and Richard A. Gonzalez as Executive Chairman of the Board of Directors

Fourth quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on May 15, 2024

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

Consensus EPS estimates fall by 13%

AbbVie's VYALEV™? (foslevodopa/Foscarbidopa Solution) Available for the Treatment of Advanced Parkinson's Disease in Canada

AbbVie: Things Are Getting Clearer

AbbVie Inc. Reports Unaudited Intangible Asset Impairment for the Quarter Ended December 31, 2023

AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade)

AbbVie Inc. Launches Produodopa (Foslevodopa/Foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union

Abbvie Inc. Announces Phase 2 Results Showing Adults with Moderate to Severe Hidradenitis Suppurativa

AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.55

AbbVie Inc. to Report Q4, 2023 Results on Feb 02, 2024

Upcoming dividend of US$1.55 per share at 3.8% yield

AbbVie: Time To Lock In Gains (Rating Downgrade)

AbbVie Vs. GSK: Dual Dominance In Pharma

AbbVie's (NYSE:ABBV) Upcoming Dividend Will Be Larger Than Last Year's

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) for $8.2 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

AbbVie Inc. Announces Positive Topline Results from Phase 2 Luminosity Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer

4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024

AbbVie Announces U.S. Food and Drug Administration and European Medicines Agency Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

AbbVie (NYSE:ABBV) Has Announced That It Will Be Increasing Its Dividend To $1.55

AbbVie Announces U.S. Food and Drug Administration and European Medicines Agency Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks

AbbVie Announces Results Evaluating the Efficacy, Safety, and Tolerability of UBRELVY

AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.55

AbbVie Stock Still A Hold Despite Positive Third Quarter 2023 Results

Abbvie Inc. Declares Quarterly Dividend, Payable on February 15, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profit margin trend

Lupus Therapeutics Partners with AbbVie Inc. on Clinical Trial Recruitment Efforts in SLE Through Lucin Lupus Clinical Trial Network

AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldn't Derail Growth Plans

Abbvie Inc. Epkinly™ (Epcoritamab Injection/Epcoritamab for Injection) Receives Health Canada Authorization with Conditions as the First and Only Subcutaneous Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)

AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014

AbbVie Presents Positive Results from Head-to-Head Phase 3 Sequence Study in Crohn's Disease Meets All Primary and Secondary Endpoints

AbbVie Inc. Announces Director Appointments

AbbVie Inc. Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (Upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento